The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Share News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,419.00
Bid: 1,417.00
Ask: 1,419.00
Change: -9.00 (-0.63%)
Spread: 2.00 (0.141%)
Open: 1,426.00
High: 1,443.00
Low: 1,409.00
Prev. Close: 1,428.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Indivior puts biggest investor on board in overhaul

Wed, 24th Mar 2021 07:56

(Sharecast News) - Indivior has given Scopia Capital, its biggest investor, a place on its board as part of a governance overhaul by the prescription drugs group.
Jerome Lande, a partner at Scopia, will be one of four new non-executive directors. Scopia is Indivior's biggest shareholder with a 16.9% stake in the company.

Lande will be joined on the board by Juliet Thompson, a former investment banker and adviser to drugs groups; former GlaxoSmithKline executive Jo Le Couillard; and pharmaceutical industry veteran Mark Stejbach.

They all join with immediate effect and will replace Daniel Tasse, Lorna Parker, Dan Phelan and Tom McLellan, who all joined the company when it was split off from Reckitt Benckiser in 2014. Tasse and Parker will step down at the next annual meeting, Phelan will leave by the end of 2022 and McLellan will serve until November 2023.

The directors presided over a mis-selling scandal that cost Indivior $600m of fines and resulted in its former chief executive, Shaun Thaxter, going to prison in the US. Former chief financial officer Mark Crossley replaced Thaxter in June and Graham Hetherington joined as chairman in November

In November, Indivior settled a case with the US Department of Justice that accused the company of fraudulently claiming its Suboxone Film was better and safer than other opioid addiction treatments. The company also referred patients to doctors it knew to be prescribing opioids in a careless manner, the indictment said.

"After a period of significant strategic change and decisive actions to better position Indivior for future value creation ... we are pleased to welcome the new NEDs to the board," Hetherington said. "Indivior's board and leadership team are committed to engaging actively with shareholders to better understand their views and we fully support and look forward to Jerome's perspectives as a representative of our largest shareholder."

With Lande on the board, Scopia has agreed not to exercise more than 20% of voting rights in the company "from time to time", to vote for ordinary resolutions recommended by the board and to vote consistently with board recommendations.

Indivior is looking for another, preferably female, non-executive director and will draw up a shortlist in consultation with Scopia.









More News
19 Nov 2020 10:30

Indivior Promotes Former Shire CFO Graham Hetherington To Chair

Indivior Promotes Former Shire CFO Graham Hetherington To Chair

Read more
13 Nov 2020 17:21

LONDON MARKET CLOSE: Vaccine Enthusiasm Fades As Case Numbers Rise

LONDON MARKET CLOSE: Vaccine Enthusiasm Fades As Case Numbers Rise

Read more
13 Nov 2020 11:13

UK WINNERS & LOSERS SUMMARY: Galliford Rises As Dividend Set To Return

UK WINNERS & LOSERS SUMMARY: Galliford Rises As Dividend Set To Return

Read more
13 Nov 2020 08:19

Indivior Happy To Put Suboxone Matter Behind It As Court Approves Deal

Indivior Happy To Put Suboxone Matter Behind It As Court Approves Deal

Read more
13 Nov 2020 07:45

LONDON MARKET PRE-OPEN: Galliford Try Expects To Reinstate Dividends

LONDON MARKET PRE-OPEN: Galliford Try Expects To Reinstate Dividends

Read more
13 Nov 2020 07:03

Indivior's settlement with DoJ approved by US court

(Sharecast News) - Indivior said a US court approved its agreement with the Department of Justice and other agencies and dismissed charges related to sales of its Suboxone opioid addiction treatment.

Read more
29 Oct 2020 12:50

Indivior Q3 profit, revenue decline; new FY guidance outlined

(Sharecast News) - Indivior reported a decline in third-quarter revenue and operating profit on Thursday but reinstated financial guidance as it said it expects to be profitable on an adjusted pre-tax basis for FY 2020.

Read more
29 Oct 2020 12:02

Indivior Reinstates Annual Guidance; Quarterly Profit Falls 79%

Indivior Reinstates Annual Guidance; Quarterly Profit Falls 79%

Read more
23 Oct 2020 10:40

Indivior Says Former CEO Thaxter's US Sentencing Not Related

Indivior Says Former CEO Thaxter's US Sentencing Not Related

Read more
23 Oct 2020 08:19

Former Indivior CEO sentenced in US Federal Court

(Sharecast News) - Pharmaceutical firm Indivior revealed on Friday that former chief executive Shaun Thaxter had been sentenced in United States Federal Court.

Read more
22 Oct 2020 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
24 Sep 2020 10:44

Indivior Reorganises Amid Challenges; Still In Line With Expectations

Indivior Reorganises Amid Challenges; Still In Line With Expectations

Read more
24 Sep 2020 08:35

Indivior to axe jobs, restructure as it looks to cut costs

(Sharecast News) - Opioid addiction treatment maker Indivior outlined plans on Thursday to reduce costs through job cuts and restructuring, as it looks to support long-term growth ambitions and protect its financial and operational flexibility in response to the pandemic.

Read more
4 Sep 2020 17:57

IN BRIEF: Indivior Chair Howard Pien Steps Down Immediately

IN BRIEF: Indivior Chair Howard Pien Steps Down Immediately

Read more
2 Sep 2020 19:36

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.